PHASEBIO PHARMA EPS (Basic, from Continuous Ops)

EPS (Basic, from Continuous Ops) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Basic, from Continuous Ops) growth rates and interactive chart.


Highlights and Quick Summary

  • EPS (Basic, from Continuous Ops) for the quarter ending June 29, 2021 was -0.6 (a -31.65% decrease compared to previous quarter)
  • Year-over-year quarterly EPS (Basic, from Continuous Ops) decreased by -30.48%
  • Annual EPS (Basic, from Continuous Ops) for 2020 was -3.39 (a 137.63% increase from previous year)
  • Annual EPS (Basic, from Continuous Ops) for 2019 was -1.43 (a -68.24% decrease from previous year)
  • Annual EPS (Basic, from Continuous Ops) for 2018 was -4.5 (a -67.41% decrease from previous year)
  • Twelve month EPS (Basic, from Continuous Ops) ending June 29, 2021 was -3.37 (a -10.12% decrease compared to previous quarter)
  • Twelve month trailing EPS (Basic, from Continuous Ops) increased by 22.19% year-over-year
Trailing EPS (Basic, from Continuous Ops) for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-3.37 -3.75 -3.39 -2.76
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Basic, from Continuous Ops) of PHASEBIO PHARMA

Most recent EPS (Basic, from Continuous Ops)of PHAS including historical data for past 10 years.

Interactive Chart of EPS (Basic, from Continuous Ops) of PHASEBIO PHARMA

PHASEBIO PHARMA EPS (Basic, from Continuous Ops) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.6 -0.87
2020 -1.04 -0.86 -0.98 -0.52 -3.39
2019 -0.4 -0.4 -0.33 -0.3 -1.43
2018 20.8 -10.45 -8.95 -5.9 -4.5
2017 -3.45 -13.79

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.